Welcome to
The Tarceva TLC Nursing Website
Patient Management Considerations
with TARCEVA® (erlotinib)

Please click on the Nurse Dinner Programs link below to review a schedule and register for a dinner program. These programs have been designed to meet the needs of oncology nurses.

Please note this is a promotional program and CEUs will not be offered.

» Nurse Dinner Programs


Indications
TARCEVA monotherapy is indicated for the treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

Results from two multinational, placebo-controlled, randomized, Phase III trials conducted in patients with locally advanced or metatstatic NSCLC showed no clinical benefit from the concurrent administration of Tarceva with platinum-based chemotherapy (carboplatin and paclitaxel or gemcitabine and cisplatin), and its use is not recommended in that setting.

TARCEVA in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Important Safety Information
  • There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events, including fatalities, in patients receiving Tarceva for treatment of NSCLC, pancreatic cancer or other advanced solid tumors.
  • Cases of hepatic failure, hepatorenal syndrome, acute renal failure (all including fatalities), and renal insufficiency have been reported during use of Tarceva.
  • Gastrointestinal perforation (including fatalities) has been reported in patients receiving Tarceva.
  • Bullous, blistering and exfoliative skin conditions have been reported including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, which in some cases were fatal.
  • In the pancreatic cancer trial, other serious adverse reactions associated with Tarceva plus gemcitabine and which may have included fatalities, were myocardial infarction/ischemia, cerebrovascular accident and microangiopathic hemolytic anemia with thrombocytopenia.
  • Corneal perforation and ulceration have been reported during use of Tarceva.
  • When receiving Tarceva therapy, women should be advised against becoming pregnant or breastfeeding. Tarceva is pregnancy category D.
  • The most common adverse reactions in patients with NSCLC receiving Tarceva monotherapy 150 mg were rash and diarrhea.
  • The most common adverse reactions in patients with pancreatic cancer receiving Tarceva 100 mg plus gemcitabine were fatigue, rash, nausea, anorexia and diarrhea.
Please click here for full prescribing information including additional important safety information.